{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:22Z","timestamp":1794047362711,"version":"4.8.0"},"reference-count":25,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel at our institution on two clinical trials, ZUMA-1 (clinicaltrials gov. Identifier: NCT02348216) and ZUMA-9 (clinicaltrials gov. Identifier: NCT03153462). Complete blood counts, lymphocyte subsets, and immunoglobulin levels were measured serially until month 24 or progression. Fifteen (48%) patients had grade 3-4 cytopenia, including anemia (five, 16%), neutropenia (nine, 29%), or thrombocytopenia (13, 42%) at day 30. Cytopenia at day 30 was not significantly associated with later diagnosis of myelodysplasia. Among patients with ongoing remission, grade 3-4 cytopenia was observed in one of nine (11%) at 2 years. While peripheral CD8+ T cells recovered early, CD4+ T-cell recovery was delayed with a count of &lt;200\/mL in three of nine (33%) patients at 1 year and two of seven (29%) at 2 years. Immunoglobulin G levels normalized in five of nine (56%) patients at 2 years. Thirteen (42%) patients developed grade 3-4 infectious complications, including herpes zoster and Pneumocystis jiroveci pneumonia. These results suggest the need for prolonged monitoring and prophylaxis against opportunistic infections in these patients, to improve the longterm safety of axicabtagene ciloleucel therapy.<\/jats:p>","DOI":"10.3324\/haematol.2020.254045","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T14:28:00Z","timestamp":1596119280000},"page":"2667-2672","source":"Crossref","is-referenced-by-count":138,"title":["Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma"],"prefix":"10.3324","volume":"106","author":[{"family":"Paolo Strati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ankur Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sherry Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Loretta J. Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jason Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Fredrick B. Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nathan H. Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hun J. Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Luis E. Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Felipe Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sairah Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yiming Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sandra Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sara Arafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Swapna Johncy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Partow Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Victor Eduardo Mulanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ella Ariza Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sattva S. Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"30049","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"30050","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"30051","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell l,ymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"30052","doi-asserted-by":"crossref","unstructured":"Strati P, Neelapu SS. Chimeric antigen receptor- engineered T cell therapy in lymphoma. Curr Oncol Rep. 2019; 21(5):38.","DOI":"10.1007\/s11912-019-0789-z"},{"key":"30053","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Tummala S, Kebriaei P. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15(1):47-62.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"30054","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"30055","doi-asserted-by":"crossref","unstructured":"Fried S, Avigdor A, Bielorai B. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650.","DOI":"10.1038\/s41409-019-0487-3"},{"key":"30056","doi-asserted-by":"crossref","unstructured":"Raje N, Berdeja J, Lin Y. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380(18):1726-1737.","DOI":"10.1056\/NEJMoa1817226"},{"key":"30057","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Pivotal safety and efficacy results from transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas. Blood. 2019; 134(Suppl 1):S241.","DOI":"10.1182\/blood-2019-127508"},{"key":"30058","doi-asserted-by":"crossref","unstructured":"Shah NN, Highfill SL, Shalabi H. CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti- CD22 CAR T-cell trial. J Clin Oncol. 2020; 38(17):1938-1950.","DOI":"10.1200\/JCO.19.03279"},{"key":"30059","doi-asserted-by":"crossref","unstructured":"Lee DW, Gardner R, Porter DL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"30060","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"30061","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Neuberg D, Stone RM. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17(10):3128-3135.","DOI":"10.1200\/JCO.1999.17.10.3128"},{"key":"30062","doi-asserted-by":"crossref","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV. Late Events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020; 26(1):26-33.","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"30063","doi-asserted-by":"crossref","unstructured":"Strati P, Wierda W, Burger J. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and newonset cytopenia. Cancer-Am Cancer Soc. 2013; 119(21):3805-3811.","DOI":"10.1002\/cncr.28318"},{"key":"30064","doi-asserted-by":"crossref","unstructured":"Tam CS, O'Brien S, Wierda W. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112(4):975-980.","DOI":"10.1182\/blood-2008-02-140582"},{"key":"30065","doi-asserted-by":"crossref","unstructured":"Brudno JN, Somerville RP, Shi V. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016; 34(10):1112-1121.","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"30066","doi-asserted-by":"crossref","unstructured":"Bensinger W, Appelbaum F, Rowley S. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995; 13(10):2547-2555.","DOI":"10.1200\/JCO.1995.13.10.2547"},{"key":"30067","doi-asserted-by":"crossref","unstructured":"Hill JA, Li D, Hay KA. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018; 131(1):121-130.","DOI":"10.1182\/blood-2017-07-793760"},{"key":"30068","doi-asserted-by":"crossref","unstructured":"Park JH, Romero FA, Taur Y. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018; 67(4):533-540.","DOI":"10.1093\/cid\/ciy152"},{"key":"30069","doi-asserted-by":"crossref","unstructured":"Jung AC, Paauw DS. Diagnosing HIV-related disease: using the CD4 count as a guide. J Gen Intern Med. 1998; 13(2):131-136.","DOI":"10.1046\/j.1525-1497.1998.00031.x"},{"key":"30070","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Svoboda J, Chong EA. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377(26):2545-2554.","DOI":"10.1056\/NEJMoa1708566"},{"key":"30071","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127(26):3321-3330.","DOI":"10.1182\/blood-2016-04-703751"},{"key":"30072","doi-asserted-by":"crossref","unstructured":"Hattori N, Saito B, Sasaki Y. Status of natural killer cell recovery in day 21 bone marrow after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2018; 24(9):1841-1847.","DOI":"10.1016\/j.bbmt.2018.05.007"},{"key":"30073","doi-asserted-by":"crossref","unstructured":"Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant. 2008; 14(3):323-334.","DOI":"10.1016\/j.bbmt.2007.12.497"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9836\/71129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9836\/71130","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9836\/71129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:49Z","timestamp":1794045469000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.254045","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}